DexCom’s (DXCM) Overweight Rating Reiterated at Piper Jaffray Companies

DexCom (NASDAQ:DXCM)‘s stock had its “overweight” rating restated by analysts at Piper Jaffray Companies in a research note issued on Monday, The Fly reports.

A number of other equities analysts also recently issued reports on the company. Bank of America upped their price target on DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Morgan Stanley upped their price target on DexCom from $175.00 to $202.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Raymond James upped their price target on DexCom from $172.00 to $189.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Stifel Nicolaus upped their price target on DexCom from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, BTIG Research reaffirmed a “hold” rating on shares of DexCom in a research report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $190.67.

Shares of DXCM stock opened at $208.37 on Monday. The business’s fifty day simple moving average is $161.42 and its 200-day simple moving average is $148.82. The company has a market cap of $18.56 billion, a PE ratio of 694.57 and a beta of 0.64. The company has a current ratio of 5.63, a quick ratio of 5.26 and a debt-to-equity ratio of 1.41. DexCom has a 12-month low of $105.05 and a 12-month high of $208.38.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.45. The business had revenue of $396.30 million for the quarter, compared to the consensus estimate of $348.99 million. DexCom had a positive return on equity of 16.16% and a negative net margin of 12.68%. The business’s quarterly revenue was up 48.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.17 earnings per share. On average, equities analysts forecast that DexCom will post 1.41 earnings per share for the current year.

In related news, Director Nicholas Augustinos sold 1,208 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $185.29, for a total value of $223,830.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Andrew K. Balo sold 9,107 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $151.56, for a total value of $1,380,256.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 95,222 shares of company stock worth $14,846,206. 0.88% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of DXCM. Price T Rowe Associates Inc. MD boosted its holdings in DexCom by 359.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,456,834 shares of the medical device company’s stock valued at $817,652,000 after purchasing an additional 4,268,926 shares during the last quarter. Nuveen Asset Management LLC boosted its holdings in DexCom by 1,781.3% in the second quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock valued at $165,983,000 after purchasing an additional 1,048,855 shares during the last quarter. Jennison Associates LLC boosted its holdings in DexCom by 211.2% in the second quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock valued at $208,574,000 after purchasing an additional 944,642 shares during the last quarter. First Trust Advisors LP boosted its holdings in DexCom by 358.1% in the third quarter. First Trust Advisors LP now owns 279,121 shares of the medical device company’s stock valued at $41,656,000 after purchasing an additional 218,188 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its holdings in DexCom by 89.5% in the second quarter. Orbimed Advisors LLC now owns 262,900 shares of the medical device company’s stock valued at $39,393,000 after purchasing an additional 124,200 shares during the last quarter. 98.21% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What are the benefits of investing in REITs?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.